Skip to main content

Advertisement

SpringerLink
Log in

Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Purpose

Genetic factors have a role in response to a target medication (personalized medicine). This study aimed to review available evidence about the relationship between gene variants and therapeutic response to sulfonylureas in type 2 diabetes, systematically.

Methods

An extensive search was done in Scopus, PubMed, and Web of Science with specific search strategy in the field from the beginning until the 1st of Jan. 2021. After sending records to endnote software and removing duplicate records remained documents were screened by title and abstract. Full texts of remained documents were assessed after removing un-related records. Required data was extracted from remained documents and records were categorized according to gene/SNP studied.

Results

Finally, 26 studies with 9170 T2DM patients with a mean age of 59.47 ± 6.67 (49.7–75.2 years) remained. The most contribution was from China, Slovakia and Greece, respectively and the most genes studied were CYP2C9, KCNJ11, and both KCNQ1 and ABCC8 with 10, 7, and 4 articles, respectively. Also, rs1799853 and rs1057910 (each with seven studies), rs5219 with six studies and CYP2C9*1(with four articles), respectively were the most common variants investigated. Studies about each gene obtained different positive or negative results and were not consistent.

Conclusion

Considering heterogeneity between SFUs pharmacogenomic studies regarding the method, sample size, population, gene/variant studied, and outcome and findings, these studies are not conclusive and need further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

Data is available on request.

Code availability

Not applicable.

References

  1. International Diabetes Federation. IDF Diabetes Atlas. 2019: Brussels; Belgium.

  2. García-Chapa EG, Leal-Ugarte E, Jebari S, Larrea-Seba A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21:6275.

    Article  Google Scholar 

  3. Akhondzadeh S. Personalized medicine: a tailor made medicine. Avicenna J Med Biotechnol. 2014;6:191.

    PubMed  PubMed Central  Google Scholar 

  4. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63:437–59.

    Article  CAS  PubMed  Google Scholar 

  5. Ahmed S, Zhou Z, Zhou J, Chen S-Q. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinform. 2016;14:298–313.

    Article  Google Scholar 

  6. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics J. 2011;12:1161–91.

    Article  CAS  Google Scholar 

  7. Florez JC. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia. 2017;60:800–7.

    Article  CAS  PubMed  Google Scholar 

  8. Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care. 2014;37:876–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ashcroft FM. ATP-sensitive K channels and disease: from molecule to malady. Am J Physiol Endocrinol Metab. 2007;293:880–9.

    Article  Google Scholar 

  11. Inagaki N, Gonoi T, Clement JP, Namba N, Inazawa J, Gonzalez G, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270:1166–70.

    Article  CAS  PubMed  Google Scholar 

  12. Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiol Rev. 2010;90:291–366.

    Article  CAS  PubMed  Google Scholar 

  13. KCNJ11 gene. [cited 2021 Aug. 16]; Available from: https://medlineplus.gov/genetics/gene/kcnj11/.

  14. Walczewska-Szewc K, Nowak W. Structural Determinants of Insulin Release: Disordered N‑Terminal Tail of Kir6.2 Affects Potassium Channel Dynamics through Interactions with Sulfonylurea Binding Region in a SUR1 Partner. J Phys Chem B. 2020; 124:6198−6211.

  15. Hirst JA, Farmer AJ, Dyar A, Lung TWC, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia. 2013;56:973–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral antidiabetic agents on A1C Levels; a systematic review and meta-analysis. Diabetes Care. 2010;33:1859–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Exp Rev Cardiovasc Ther. 2010;8:359–72.

    Article  CAS  Google Scholar 

  18. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol. 2011;67:471–6.

    Article  CAS  PubMed  Google Scholar 

  19. Javorsky M, Klimcakova L, Schroner Z, Zidzik J, Babjakova E, Fabianova M, et al. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur J Intern Med. 2012;23:245–9.

    Article  CAS  PubMed  Google Scholar 

  20. Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, et al. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia. 2014;57:746–53.

    Article  CAS  PubMed  Google Scholar 

  21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

  22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  PubMed  Google Scholar 

  23. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.

  24. Zhou K, Donnelly L, Burch L, Tavendale R, Doney ASF, Leese G, et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2010;87:52–6.

    Article  CAS  PubMed  Google Scholar 

  25. Castelan-Martinez OD, Hoyo-Vadillo C, Bazan-Soto TB, Cruz M, Tesoro-Cruz E, Valladares-Salgado A. CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. J Clin Pharm Ther. 2018;43:768–74.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang HJ, Liu XM, Kuang HY, Yi R, Xing HX. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract. 2007;77:58–61.

    Article  CAS  PubMed  Google Scholar 

  27. Swen JJ, Wessels JAM, Krabben A, Assendelft WJJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus. Pharmacogenomics. 2010;11:1517–23.

    Article  CAS  PubMed  Google Scholar 

  28. Mitchell SL, Leon DAC, Chaugai S, Kawai VK, Levinson RT, Wei WQ, et al. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care. Pharmacogenomics J. 2020;20:831–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Salam RFA, Zeyada R, Osman NA. Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Comparative Clin Pathol. 2014;23:341–6.

    Article  Google Scholar 

  30. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics. 2009;10:1781–7.

    Article  CAS  PubMed  Google Scholar 

  31. Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol. 2005;60:103–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Saberi M, Ramazani Z, Rashidi H, Saberi A. The effect of CYP2C9 genotype variants in type 2 diabetes on the pharmacological effectiveness of sulfonylureas, diabetic retinopathy, and nephropathy. Vasc Health Risk Manag. 2020;16:241–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Becker ML, Visser LE, Trienekens PH, Hofman B, van Schaik RHN, Stricker BHC. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type 2 diabetes mellitus. Clin Pharmacol Ther. 2008;8:288–92.

    Article  Google Scholar 

  34. Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z. Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study. Pharmacogenomics. 2020;21:587–600.

    Article  CAS  PubMed  Google Scholar 

  35. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009;41:387–90.

    Article  CAS  PubMed  Google Scholar 

  36. Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, et al. Search for pharmacoepigenetic correlations in type 2 diabetes under sulfonylurea treaTment. Exp Clin Endocrinol Diabetes. 2019;127:226–33.

    Article  CAS  PubMed  Google Scholar 

  37. Li Q, Chen M, Zhang R, Jiang F, Wang J, Zhou J, et al. KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2014;41:748–54.

    Article  CAS  PubMed  Google Scholar 

  38. Ragia G, Tavridou A, Petridis I, Manolopoulos VG. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated Type 2 diabetic patients. Diabetes Res Clin Pract. 2012;98:119–24.

    Article  CAS  PubMed  Google Scholar 

  39. Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in chinese type 2 diabetic patients. Diabetes Care. 2008;31:1939–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 2010;11:1743–50.

    Article  CAS  PubMed  Google Scholar 

  41. Li Q, Tang TT, Jiang F, Zhang R, Chen M, Yin J, Bao YQ, Cheng X, et al. Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. Acta Pharmacol Sin. 2016;38:80–9.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Duan F, Guo Y, Zhang L, Chen P, Wang X, Liu Z, et al. Association of KCNQ1 polymorphisms with gliclazide efficacy in Chinese type 2 diabetic patients. Pharmacogenet Genomics. 2016;26:178–83.

    Article  CAS  PubMed  Google Scholar 

  43. Schroner Z, Dobrikova M, Klimcakova L, Javorsky M, Zidzik J, Kozarova M, et al. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med Sci Monit. 2011; 17: CR 392–39.

  44. Javorský M, Babjaková E, Klimčáková L, Schroner Z, Židzik J, Štolfová M, et al. Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. Int J Endocrinol. 2013;2013:374858.

  45. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney ASF, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007;56:2178–82.

    Article  CAS  PubMed  Google Scholar 

  46. Schroner Z, Javorský M, Halušková J, Klimčáková L, Babjaková E, Fabianová M, et al. Variation in CDKAL1 gene is associated with therapeutic response to sulphonylureas. Physiol Res. 2012;61:77–83.

    Google Scholar 

  47. CYP2C9 gene. 2021 [cited 2021 Aug 15]; Available from: https://medlineplus.gov/genetics/gene/cyp2c9/.

  48. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12:251–63.

    Article  CAS  PubMed  Google Scholar 

  49. Wang F, Han X-Y, Ren Q, Zhang X-Y, Han L-C, Luo Y-y, et al. Effect of genetic variants in KCNJ11, ABCC8, PPARG and HNF4A loci on the susceptibility of type 2 diabetes in Chinese Han population. Chin Med J (Engl). 2009;122:2477–82

  50. Rizvi S, Raza ST, Mahdi F, Singh SP, Rajput M, Rahman Q. Genetic polymorphisms in KCNJ11 (E23K, rs5219) and SDF-1beta (G801A, rs1801157) genes are associated with the risk of type 2 diabetes mellitus. Br J Biomed Sci. 2018;75:139–44.

    Article  CAS  PubMed  Google Scholar 

  51. Makhzoom O, Kabalan Y, Al-Quobaili F. Association of KCNJ11 rs5219 gene polymorphism with type 2 diabetes mellitus in a population of Syria: a case-control study. BMC Med Genet. 2019;20:107.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Khodaeian M, Enayati S, Tabatabaei-Malazy O, Amoli MM. Association between Genetic Variants and Diabetes Mellitus in Iranian Populations: A Systematic Review of Observational Studies. J Diabetes Res. 2015;2015:585917.

  53. KCNQ1 gene. 2021 [cited 2021 Aug. 16]; Available from: https://medlineplus.gov/genetics/gene/kcnq1/.

  54. Li Y, Wang X, Lu X-Z. KCNQ1 rs2237892 C→T gene polymorphism and type 2 diabetes mellitus in the Asian population: a meta-analysis of 15,736 patients. J Cell Mol Med. 2014;18:274–82.

    Article  CAS  PubMed  Google Scholar 

  55. Li Y, Shen K, Li C, Yang Y, Yang M, Tao W, et al. Identifying the association between single nucleotide polymorphisms in KCNQ1, ARAP1, and KCNJ11 and type 2 diabetes mellitus in a Chinese population. Int J Med Sci. 2020;17:2379–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bakhtiyari A, Haghani K, Bakhtiyari S, Zaimy MA, Zahed N, Gheysarzadeh A, et al. Association between ABCC8 Ala1369Ser Polymorphism (rs757110 T/G) and type 2 diabetes risk in an iranian population: a case-control study. Endocr Metab Immune Disord Drug Targets. 2021;21:441–7.

    Article  CAS  PubMed  Google Scholar 

  57. Viji D, Aswathi P, Pricilla Charmine P, Akram Husain RS, Noorul Ameen S, Ahmed SSSJ, et al. Genetic association of ABCC8 rs757110 polymorphism with type 2 diabetes mellitus risk: a case-control study in South India and a meta-analysis. Gene Rep. 2018;13:220–8.

    Article  Google Scholar 

  58. IRS1 Gene 2021 [cited 2021 Aug. 16]; Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=IRS1.

  59. García-Chapa EG, Leal-Ugarte E, Peralta-Leal V, Durán-González J, Meza-Espinoza JP. Genetic epidemiology of type 2 diabetes in mexican mestizos. Biomed Res Int. 2017;2017:3937893.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Kommoju UJ, Maruda J, Samy SK, Irgam K, Kotla JP, Reddy BM. Association of IRS1, CAPN10, and PPARG gene polymorphisms with type 2 diabetes mellitus in the high-risk population of Hyderabad. India J Diabetes. 2014;6:564–73.

    Article  CAS  PubMed  Google Scholar 

  61. Shokouhi S, Delpisheh A, Haghani K, Mahdizadeh M, Bakhtiyari S. Association of rs7903146, rs12255372, and rs290487 polymorphisms in TCF7L2 gene with type 2 diabetes in an Iranian Kurdish ethnic group. Clin Lab. 2014;60:1269–76.

    Article  CAS  PubMed  Google Scholar 

  62. Reyes-López R, Perez-Luque E, Malacara JM. Relationship of lactation, BMI, and rs12255372 TCF7L2 polymorphism on the conversion to type 2 diabetes mellitus in women with previous gestational diabetes. Gynecol Endocrinol. 2019;35:412–6.

    Article  PubMed  Google Scholar 

  63. Dhawan D, Padh H. Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics. Diabetes Res Clin Pract. 2016;121:35–40.

    Article  CAS  PubMed  Google Scholar 

  64. Palmer CJ, Bruckner RJ, Paulo JA, Kazak L, Long JZ, Mina AI, et al. Cdkal1, a type 2 diabetes susceptibility gene, regulates mitochondrial function in adipose tissue. Mol Metab. 2017;6:1212–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Peng F, Hu D, Gu C, Li X, Li Y, Jia N, et al. The relationship between five widely-evaluated variants in CDKN2A/B and CDKAL1 genes and the risk of type 2 diabetes: a meta-analysis. Gene. 2013;531:435–43.

    Article  CAS  PubMed  Google Scholar 

  66. Cuautle-Rodriguez P, Rodriguez-Rivera N, De Andres F, Castillo-Najera F, Llerena A, Molina-Guarneros JA. Frequency of CYP2C9 (*2, *3 and IVS8-109A>T) allelic variants, and their clinical implications, among Mexican patients with diabetes mellitus type 2 undergoing treatment with glibenclamide and metformin. Biomed Rep. 2019;10:283–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Ren Q, Han X, Ren J, Liu X, Ji L. Influence of the SLCO1B3 gene on sulfonylurea failure in patients with type 2 diabetes in China. Exp Clin Endocrinol Diabetes. 2017;125:449–53.

    Article  CAS  PubMed  Google Scholar 

  68. Ren Q, Han X, Zhang S, Cai X, Ji L. Combined influence of genetic variants and gene-gene interaction on sulfonylurea efficacy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2016; 124:157–62.69.

  69. Zeng WT, Guo YL, Chen PX, Liu ZK, Chen DF, Han CJ. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients. J Diabetes Invest. 2016;7:764–8.

    Article  CAS  Google Scholar 

  70. Holstein JD, Patzer O, Korner A, Stumvoll M, Kovacs P, Holstein A. Genetic variants in GCKR, GIPR, ADCY5 and VPS13C and the risk of severe sulfonylurea-induced hypoglycaemia in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013;121:54–7.

    CAS  PubMed  Google Scholar 

  71. Aguilar-Salinas CA, Muñoz-Hernandez LL, Cobos-Bonilla M, Ramírez-Márquez MR, Ordoñez-Sanchez ML, Mehta R, et al. The R230C variant of the ATP binding cassette protein A1 (ABCA1) gene is associated with a decreased response to glyburide therapy in patients with type 2 diabetes mellitus. Metabolism. 2013;62:638–41.

    Article  CAS  PubMed  Google Scholar 

  72. Suzuki K, Yanagawa T, Shibasaki T, Kaniw N, Hasegawa R, Tohkin M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with Type 2 diabetes. Diabetes Res Clin Pract. 2006;72:148–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Leyla Karkhaneh

  2. Physiology Department, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    Leyla Karkhaneh

  3. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Ozra Tabatabaei-Malazy

  4. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, 5th Flat, Diabetes Clinic, Cross Heyat Ave., Shahrivar Ave., North Kargar St., Tehran, Iran

    Fatemeh Bandarian

  5. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Shahrzad Mohseni & Bagher Larijani

Authors
  1. Leyla Karkhaneh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ozra Tabatabaei-Malazy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatemeh Bandarian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shahrzad Mohseni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bagher Larijani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FB: Concept and design, Literature search and data collection, analysis, interpretation of results, writing the first manuscript draft, approving the final manuscript. BL: Concept and design, approving the final manuscript. LK, SM, OTM: Literature search and data collection, writing the first manuscript draft, approving the final manuscript.

Corresponding authors

Correspondence to Ozra Tabatabaei-Malazy or Fatemeh Bandarian.

Ethics declarations

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

All authors consented to publish.

Conflict of interest

Authors have no conflict of interest to declare.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Karkhaneh, L., Tabatabaei-Malazy, O., Bandarian, F. et al. Pharmacogenomics of sulfonylureas in type 2 diabetes mellitus; a systematic review. J Diabetes Metab Disord 21, 863–879 (2022). https://doi.org/10.1007/s40200-021-00908-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-021-00908-x

Keywords

Search

Navigation